Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label fampridine study for quality of life in multiple sclerosis
NL-OMON37416Phase 4Active, not recruiting
- Sponsor
- Biogen
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dalfampridine in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoint: Change from baseline in SF-36 Physical Component Scale. Started Feb 2012; status: active, not recruiting.
02
Drugs
dalfampridine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON37416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37416.